Mutational Landscape of PI3K-AKT-mTOR Pathway in Breast Cancer: Implications for Targeted Therapeutics, page-5

Kazia update 30 June 2021.
Paxalisib Investigator-Initiated Studies

Kazia has been advised of generally good progress across the ongoing investigator-initiated studies of paxalisib in other forms of brain cancer. As previously indicated, the company expects that the respective investigators will release initial data from several of these studies during CY2021.

---------------------------------------------------------------------------------------------------

Brain Metastases Phase II
150 Recruiting Any brain metastses with clinically validated alternation in PI3K pathway
National Cancer Institute - NCT03994796

Yes, up to 4.5 months is a long, long time to wait for some impatient shareholders.